Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylprednisolone with or without IVIg for chronic active antibody-mediated rejection after kidney transplantation
ACTRN12612000252819Phase 4Terminated
- Sponsor
- Dr William Mulley
- Start
- Sep 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of methylprednisolone, Human normal immunoglobulin G, tacrolimus, mycophenolate and prednisolone in Chronic active antibody-mediated rejection of kidney allograft (caABMR) (2 arms), sponsored by Dr William Mulley. Primary endpoint: Chronic allograft damage index score. Started Sep 2012; status: terminated.
02
Drugs
methylprednisoloneHuman normal immunoglobulin Gtacrolimusmycophenolateprednisolone
03
Conditions
Chronic active antibody-mediated rejection of kidney allograft (caABMR)
Beyond the preview
Go deeper on ACTRN12612000252819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000252819.